Thank you for highlighting this important MHRA Drug Safety Update
Glucagon-Like Peptide 1 Receptor Agonists and Coronary Events Composite Outcomes Including Coronary Events Coronary events form a part of cardiovascular composite outcomes, such as cardiovascular mortality and major adverse cardiovascular events (MACE)
The FDA has approved specific GLP-1 medications for type 2 diabetes management and, in higher doses, certain agents (semaglutide 2.4 mg, liraglutide 3 mg, tirzepatide) for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity
Retatrutide , a triple agonist that activates GLP-1, GIP, and glucagon receptors simultaneously, is in advanced clinical trials
K.McbrideS
A 2010 research study in rats found that when given BPC-157, faster improvements in the healing of ligament and tendon damage occurred within the animals [10]